Shelly Kaushik

Shelly Kaushik

Auto-generated profile, based on publicly available information

Shelly Kaushik

Center for Bioengineering and Tissue Regeneration, Department of Surgery, University of California, San Francisco, San Francisco, CA, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2016 in Cancer and Metastasis Reviews
Verified
Journal Article
Closed access
PDF file
SKShelly Kaushik
Shelly Kaushik
MPMichael W Pickup
Michael W Pickup
VWValerie M Weaver
Valerie M Weaver

10 September 2018 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
JBJ. Matthew Barnes
J. Matthew Barnes
SKShelly Kaushik
Shelly Kaushik
RBRussell O. Bainer
Russell O. Bainer
JSJason K. Sa
Jason K. Sa
EWElliot C. Woods
Elliot C. Woods
VWValerie M Weaver
Valerie M Weaver

16 December 2015 in Nature Communications
Verified
Journal Article
Open access
PDF file
YCYamicia Connor
Yamicia Connor
STSarah Tekleab
Sarah Tekleab
SNShyama Nandakumar
Shyama Nandakumar
CWCherelle Walls
Cherelle Walls
YTYonatan Tekleab
Yonatan Tekleab
SSShiladitya Sengupta
Shiladitya Sengupta
Metastasis is a major cause of mortality and remains a hurdle in the search for a cure for cancer. Not much is known about metastatic cancer cells and endothelial cross-talk, which occurs at multiple stages during metastasis. Here we report a dynamic regulation of the endothelium by cancer cells through the formation of nanoscale intercellular membrane bridges, which act as physical conduits for transfer of microRNAs. The communication between the tumour cell and the endothelium upregulates markers associated with pathological endothelium, which is reversed by pharmacological inhibition of these nanoscale conduits. These results lead us to define the notion of ‘metastatic hijack’: cancer cell-induced transformation of healthy endothelium into pathological endothelium via horizontal communication through the nanoscale conduits. Pharmacological perturbation of these nanoscale membrane bridges decreases metastatic foci in vivo. Targeting these nanoscale membrane bridges may potentially emerge as a new therapeutic opportunity in the management of metastatic cancer.

9 December 2016 in Chemical Science
Verified
Journal Article
Open access
PDF file
NGNimish Gupta
Nimish Gupta
JKJohny Kancharla
Johny Kancharla
SKShelly Kaushik
Shelly Kaushik
AAAasif Ansari
Aasif Ansari
SHSamad Hossain
Samad Hossain
SSShiladitya Sengupta
Shiladitya Sengupta
Despite the advances in the design of antibody–drug conjugates (ADCs), the search is still ongoing for novel approaches that lead to increased stability and homogeneity of the ADCs. We report, for the first time, an ADC platform technology using a platinum(II)-based linker that can re-bridge the inter-chain cysteines in the antibody, post-reduction. The strong platinum–sulfur interaction improves the stability of the ADC when compared with a standard maleimide-linked ADC thereby reducing the linker–drug exchange with albumin significantly. Moreover, due to the precise conserved locations of cysteines, both homogeneity and site-specificity are simultaneously achieved. Additionally, we demonstrate that our ADCs exhibit increased anticancer efficacy in vitro and in vivo. The Pt-based ADCs can emerge as a simple and exciting proposition to address the limitations of the current ADC linker technologies.

1 February 2015 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
ARArchna Ravi
Archna Ravi
SKShelly Kaushik
Shelly Kaushik
ARAarthi Ravichandran
Aarthi Ravichandran
CPCatherine Qiurong Pan
Catherine Qiurong Pan
BLBoon Chuan Low
Boon Chuan Low
Deleted in Liver Cancer 1 (DLC1) is a RHO GTPase-activating protein (GAP) that negatively regulates RHO. Through its GAP activity, it modulates the actin cytoskeleton network and focal adhesion dynamics, ultimately leading to suppression of cell invasion and metastasis. Despite its presence in various structural and signaling components, little is known about how the activity of DLC1 is regulated at focal adhesions. Here we show that EGF stimulation activates the GAP activity of DLC1 through a concerted mechanism involving DLC1 phosphorylation by MEK/ERK and its subsequent dephosphorylation by protein phosphatase 2A (PP2A) and inhibition of focal adhesion kinase by MEK/ERK to allow the binding between DLC1 and PP2A. Phosphoproteomics and mutation studies revealed that threonine 301 and serine 308 on DLC1, known previously to be mutated in certain cancers, are required for DLC1-PP2A interaction and the subsequent activation of DLC1 upon their dephosphorylation. The intricate interplay of this “MEK/ERK-focal adhesion kinase-DLC1-PP2A” quartet provides a novel checkpoint in the spatiotemporal control of cell spreading and cell motility.

28 November 2014 in Cytoskeleton
Verified
Journal Article
Closed access
PDF file
SKShelly Kaushik
Shelly Kaushik
ARArchna Ravi
Archna Ravi
FHFeroz M. Hameed
Feroz M. Hameed
BLBoon Chuan Low
Boon Chuan Low